SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

SELLAS Life Sciences Group Inc.

In a report released yesterday, Sam Crittenden from RBC Capital maintained a Buy rating on Solaris Resources, with a price target of C$18.00. The c...

Solaris Resources (SLSR) Receives a Rating Update from a Top Analyst

Solstice Minerals Limited ( ($AU:SLS) ) just unveiled an announcement. Solstice Minerals Limited announced a change in the interests of its directo...

Solstice Minerals Announces Director’s Interest Change

An update from Solstice Minerals Limited ( ($AU:SLS) ) is now available. Solstice Minerals Limited announced the cessation of 321,916 performance r...

Solstice Minerals Announces Cessation of Performance Rights

The latest update is out from Global Surfaces Limited ( ($IN:GSLSU) ). Global Surfaces Limited has announced a postal ballot notice seeking shareho...

Global Surfaces Limited Initiates Postal Ballot for Auditor Appointment

An announcement from Solstice Minerals Limited ( ($AU:SLS) ) is now available. Solstice Minerals Limited has announced the quotation of 223,027 ful...

Solstice Minerals Limited Announces Quotation of New Securities

Maxim Group analyst Tate Sullivan maintained a Hold rating on Solaris Resources yesterday. The company’s shares opened today at C$10.85. Sullivan c...

Maxim Group Reaffirms Their Hold Rating on Solaris Resources (SLSR)

Solesence ( ($SLSN) ) just unveiled an announcement. On November 22, 2025, Solesence, Inc. entered into a Consulting Agreement with Jess Jankowski,...

Solesence Appoints New Director After CEO Retirement

Solstice Minerals Limited ( ($AU:SLS) ) has shared an announcement. Solstice Minerals Limited has announced a change in the director’s interest not...

Solstice Minerals Updates Director’s Interest Notice

Solaris Resources Inc ( ($SLSR) ) has released its Q3 earnings. Here is a breakdown of the information Solaris Resources Inc presented to its inves...

Solaris Resources Reports Narrowed Losses and Secures Funding

An announcement from Solstice Minerals Limited ( ($AU:SLS) ) is now available. Solstice Minerals Limited announced the issuance of new unquoted equ...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	1 years
Ex-Dividend	Invalid Date	Pay Date	4/26/2012
Frequency	NA	Quarterly Est	$0.00

Date	4/27/2012	Amount	$0.00	Currency	USD	Frequency	2012-04-26
Date	3/6/2012	Amount	$0.00	Currency	USD	Frequency	Q

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLS	$2.03	+1.00%	5.66M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLS	$2.03	+1.0%	5.66M
3
4
5
6

SLS

SLS

Dividend Overview

Recent Dividend History

Get SELLAS Life Sciences Group Inc. Data in Excel

Get SELLAS Life Sciences Group Inc. Data in Excel